Press Release

Pharnext's Pivotal Phase 3 trial PLEO-CMT to be featured at the 22nd Edition of the Francophone Peripheral Nerve Society conference

PARIS, France, 5:45 pm, January 18, 2018 (CET) -Pharnext SA(FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drugs based on the combination and repositioning of known drugs, today announced the Company will present an update from its ongoing pivotal Phase 3 clinical trial PLEO-CMT evaluating PXT3003 for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), in an oral session during the 22nd edition of the Francophone Peripheral Nerve Society conference. The gathering will take place on January 26-27, 2018 in Paris (France).

Details of the presentation are as follows:

Date

Time

Session

Friday January 26, 2018

From 3:03 to 3:15pm CET

Selected Oral Communications Session

  • • Title: Status of the Pivotal Phase III Study (PLEO-CMT) Assessing the Efficacy and Safety of PXT3003 in the Treatment of Adult Patients with Charcot-Marie-Tooth type 1A

  • • Speaker : Prof. Shahram Attarian (Marseille)

For more information about the event please visit :www.journeessfnp.fr/programme

About Pharnext

Pharnext is an advanced clinical-stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States.

PXT864 has generated positive Phase 2 results in Alzheimer's disease. Pharnext is the pioneer of a new drug discovery paradigm: PLEOTHERAPY™. The Company identifies and develops synergic combinations of repositioned drugs at new optimal lower doses. These PLEODRUG™ offer several key advantages: efficacy, safety and intellectual property, including several product or composition of matter patents already granted. The Company is supported by a world-class scientific team.

Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN code: FR0011191287). For more information, visitwww.pharnext.com.

CONTACTS:

Pharnext

René Goedkoop Chief Medical Officermedical@pharnext.com +33 (0)1 41 09 22 30

Investor Relations (Europe)

MC Services AG

Anne Henneckeanne.hennecke@mc-services.eu +49 211 529252 22

Media Relations (Europe)

ALIZE RP

Caroline Carmagnol Aurore Gangloffpharnext@alizerp.com +33 (0)1 44 54 36 64

PHARNEXT | CREATING NEW SOLUTIONS

Investor Relations (U.S.)

Stern Investor Relations, Inc. Matthew Shinsekimatthew@sternir.com +1 212 362 1200

Media Relations (U.S.)

RooneyPartners Marion Janicmjanic@rooneyco.com +1 212 223 4017

Financial Communication (France)

Actifin

Stéphane Ruizsruiz@actifin.fr +33 (0)1 56 88 11 15

Page 2

Pharnext SA published this content on 18 January 2018 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 18 January 2018 16:49:08 UTC.

Original documenthttps://www.pharnext.com/images/PDF/press_releases/2018.01.18_SFNP_EN.pdf

Public permalinkhttp://www.publicnow.com/view/AD8D5C4EFC75B47EEC3F66B9681CDB4F21F34036